Global biomedical industry leaders gather in the sand to share research and development achievements of peptide drugs

Reprinted in Netease News Yesterday, the fourth global peptide research and development conference, jointly sponsored by Hangzhou Economic and Technological Development Zone and China peptide Biochemical Co., Ltd., kicked off Zhou Tao, deputy secretary of the Party Working Committee of the Development Zone, attended the meeting and delivered a speech Zhou Tao pointed out that in recent years, the development zone has vigorously implemented the innovation driven strategy, made great efforts to build key high-tech industries such as biomedicine, electronic information, new energy and new materials, and attracted a group of high-end talents and high-tech projects from overseas In terms of biomedical industry, relying on the construction of "Eastern medicine port town", the development zone has successively introduced international leading enterprises such as Pfizer, MSD, Lilly, Gilead and Bayer Half of the top ten pharmaceutical companies in the world have invested and started businesses in the development zone Zhou Tao said that driven by the industrial agglomeration effect, the development zone will speed up the implementation of the "three multipliers" action plan of biomedical talent projects, scientific and technological achievements and performance contributions, realize the intensive development of biomedical health industry cluster, and strive to build a biomedical high-end talent concentration zone, high-tech industry pilot zone and advanced technology bearing zone The global peptide R & D conference is an annual event in the field of global biomedicine, attracting the participation of famous peptide drug R & D enterprises, peptide experts from famous universities, experts from the China US drug administration, USP and famous venture capital institutions in the field of global biopharmaceutics It is understood that this global peptide R & D conference lasted for three days, covering four major themes of peptide drug R & D, production, quality and regulations - overview of peptide drug development and prospect, peptide new drug R & D and new technology, peptide drug clinical case sharing, and peptide drug GMP production, quality research, regulations and application, etc Yesterday's professional forum was hosted by Dr Li Xiang, chairman of sinopeptide biochemical, and Dr Xu Qi, general manager During this period, a number of peptide drug R & D enterprises and University experts shared the latest achievements in peptide R & D and treatment, as well as the technology and achievements of industrialization On site Q & A interaction is frequent and the exchange atmosphere is strong Next, there will be a number of symposiums, one-to-one talks, and visits to the newly built GMP production and R & D building of China peptide Founded in 2001, China peptide Biochemical Co., Ltd is a leading peptide service provider in the world The company has long served major pharmaceutical companies at home and abroad, and is also a strategic partner of peptide pharmaceutical companies in R & D and industrialization "This is the industry academic and industry R & D conference held by peptide bio for global customers, and this year is the fourth one." Cheng Tao, chief business officer of China peptide bio chemical Co., Ltd., said that as an enterprise, China peptide bio chemical Co., Ltd can hold four consecutive grand gatherings gathering the industry's top people without the support of the Management Committee of the development zone She said that this year's global peptide R & D conference continued the previous discussion topics, from R & D to clinical peptide treatment, as well as the discussion of application regulations around quality standards At the same time, the meeting will also discuss the content of biomedical venture capital to build an industrial platform for new technologies "In the process of new drug research and development, the establishment of quality standards is the key to the success of application This time, we are very honored to invite colleagues from USP to give a one-day lecture on quality standards to help pharmaceutical companies understand and discuss the latest knowledge of new drug laws and regulations, and carry out new drug research and development and registration more smoothly " Cheng Tao said he hopes to provide practical help to customers and help the development of China's pharmaceutical industry through lectures and exchanges in the past few days.